FiledIMAGE / Shutterstock.com
As well as much other debate, the High Court’s decision in D’Arcy v Myriad Genetics has created uncertainty in terms of the patent eligibility of naturally occurring molecules other than DNA, says Tania Obranovich, special counsel at Watermark Intellectual Asset Management.
In the highly anticipated decision in D’Arcy v Myriad Genetics, handed down earlier this month, the High Court of Australia has unanimously held that isolated naturally occurring DNA is not eligible for patent protection. This decision overturned two earlier Federal Court decisions (Cancer Voices Australia v Myriad Genetics 2013 and D’Arcy v Myriad Genetics 2014) which had unanimously upheld the patent eligibility of isolated DNA, specifically the isolated BRCA DNA which was the subject of Myriad’s Australian patent number 686004.
This decision has reversed decades of accepted practice in Australia in relation to patent eligibility and although now arguably aligning Australian patent eligibility practice more closely with that of the US, nevertheless sets it at odds with most other jurisdictions, including all of Australia’s major trading partners.
Australian effects
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Tania Obranovich, Watermark Intellectual Asset Management, DNA, D'Arcy v Myriad Genetics, Australia, cDNA, patent, USPTO, TPP,
